Humanwell Healthcare's Subsidiary Secures FDA Approval for Diltiazem Hydrochloride Tablets
Stock News
4 hours ago
Humanwell Healthcare (Group) Co., Ltd. (ASX: 600079.SH) announced that its controlling subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd. (Yichang Humanwell), has received approval from the U.S. Food and Drug Administration (FDA) for diltiazem hydrochloride tablets.
The drug is primarily indicated for the treatment of chronic stable angina and angina caused by coronary artery spasm.
This approval signifies that Yichang Humanwell is now qualified to market the product in the United States, which is expected to have a positive impact on the company's efforts to expand into the U.S. generic drug market. Yichang Humanwell will subsequently advance preparations for launching the product in the U.S. market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.